Doxorubicin (Adriamycin) Triggers HMGB1-Dependent Inflammatory Apoptosis Induced by Severe Oxidative and Nitrosative Stress

Explore how Doxorubicin (Adriamycin) drives mitochondrial ROS, peroxynitrite generation, HMGB1 translocation, and apoptotic-pyroptotic cell death cascades.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Enzymatic one-electron reduction of the doxorubicin quinone ring catalyzes futile redox cycling, yielding cytotoxic flux of \ce{O2^{\bullet-}} and \ce{H2O2} [1].
  • 2
    Endothelial nitric oxide synthase uncoupling accelerates the diffusion-limited generation of peroxynitrite (\ce{ONOO-}), driving cardiolipin oxidation and mitochondrial decay [2][3].
  • 3
    Oxidative DNA lesions and Top2β cleavage complexes provoke severe PARP-1 activation, depleting \ce{NAD+} pools and triggering SIRT1-dependent HMGB1 hyperacetylation [2][4].
  • 4
    Nucleocytoplasmic translocation of disulfide-bonded HMGB1 promotes autocrine and paracrine stimulation of TLR4 and RAGE, amplifying executioner Caspase-3 cleavage [5][6].
  • 5
    Caspase-3-mediated cleavage of Gasdermin E (GSDME) converts apoptotic kinetics into secondary necrotic lysis with immunogenic DAMP release [6][7].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
EXTRACELLULAR PLASMA MEMBRANE CYTOPLASM NUCLEUS DOXORUBICIN SIGNALING CASCADE P=Phospho | ->=Activate | -|=Inhibit Doxorubicin Rate >6.7e9/M/s TLR4/MD-2 RAGE HMGB1 Top2β PARP-1 SIRT1 HMGB1 Ac CRM1 HMGB1 MyD88 IKK P NF-κB p65 p38 MAPK P TNF-α, IL-6 Redox Cycling ONOO- / ROS ROS Bax / Bak Cyto c / Smac Caspase-9 / -3
Signaling Cascade of Doxorubicin-Induced Oxidative Stress, HMGB1 Mobilization, and Caspase-3/GSDME-Mediated Cell Death.

A detailed cellular signaling pathway schematic depicting: In the mitochondrion, Complex I-driven quinone cycling generates O2•- and ONOO-, oxidizing cardiolipin and causing cytochrome c release. In the nucleus, Top2β inhibition and PARP-1 activation deplete NAD+, inhibiting SIRT1 and inducing HMGB1 hyperacetylation and CRM1 export. In the extracellular space, disulfide-HMGB1 binds TLR4 and RAGE, activating MyD88/NF-κB and amplifying Caspase-3/GSDME pore formation at the plasma membrane.

Quinone Redox Cycling and Mitochondrial Peroxynitrite Generation

The cytotoxic pharmacology of doxorubicin initiates through enzymatic redox cycling of its anthraquinone core, a pathway distinct from its nuclear intercalating properties [1]. Intracellular oxidoreductases, including mitochondrial NADH dehydrogenase (Complex I) and NADPH-cytochrome P450 reductase, catalyze a univalent electron transfer to the quinone moiety of ring C, generating a transient doxorubicin semiquinone radical [1]. Under physiological oxygen tension, this intermediate transfers its unpaired electron to molecular O₂, regenerating the parent quinone while yielding high concentrations of superoxide anions (O₂^{\bullet-}) and secondary hydrogen peroxide (H₂O₂) [1]. Doxorubicin also binds endothelial nitric oxide synthase (eNOS) and iron cations, producing doxorubicin-Fe³⁺ coordination complexes that stimulate constitutive nitric oxide (^{\bulletNO}) synthesis while uncoupling electron transfer [2]. The bimolecular reaction of O₂^{\bullet-} with ^{\bulletNO} occurs at a diffusion-controlled rate exceeding 6.7 × 10[1] M^{-1 s^{-1}}, yielding the potent oxidant peroxynitrite (ONOO-) [2].

Peroxynitrite and downstream hydroxyl radicals execute non-enzymatic peroxidation of polyunsaturated fatty acids within the inner mitochondrial membrane, primarily targeting cardiolipin [2][3]. Cardiolipin degradation releases bound cytochrome c into the intermembrane space and disrupts electron transport supercomplex stability [2]. Concomitant generation of toxic reactive aldehydes, including 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA), induces covalent adduction of succinate dehydrogenase and mitochondrial respiratory enzymes [3]. This lipid peroxidation cascades into opening of the mitochondrial permeability transition pore (mPTP), precipitating loss of mitochondrial transmembrane potential (ΔΨm) and bioenergetic collapse [2]. Table 1 benchmarks the comparative pharmacological and redox parameters of doxorubicin alongside classical anthracycline and anthracenedione analogs.

Topoisomerase II Disruption and Post-Translational HMGB1 Mobilization

While redox cycling destabilizes mitochondrial integrity, doxorubicin physically intercalates into genomic DNA to poison topoisomerase IIβ (Top2β), stabilizing covalent Top2β-DNA cleavage complexes that inhibit non-homologous end joining and cause persistent double-strand breaks [2][4]. The simultaneous burden of Top2β-mediated strand breaks and reactive oxygen/nitrogen species (RONS)-induced 8-nitroguanine base modifications drives robust activation of poly(ADP-ribose) polymerase-1 (PARP-1) [2][4]. Excessive PARP-1 enzymatic turnover consumes intracellular NAD+ stores, leading to cellular ATP depletion and downregulating the catalytic activity of the NAD+-dependent deacetylase Sirtuin-1 (SIRT1) [2][4]. Under normal baseline homeostasis, SIRT1 maintains High Mobility Group Box 1 (HMGB1) in a hypoacetylated state, preserving its high affinity for the minor groove of nuclear chromatin [4][5].

Inactivation of SIRT1, paired with activation of nuclear acetyltransferases, drives hyperacetylation of lysine residues located within the dual nuclear localization sequences of HMGB1 (NLS1: Lys28–Lys30; NLS2: Lys180–Lys184) [4][5]. Hyperacetylation neutralizes positive charges critical for histone and chromatin interaction, inducing dissociation of HMGB1 from DNA [4]. Concurrently, intracellular oxidative shifts modify the redox state of three critical conserved cysteine residues within HMGB1: Cys23, Cys45, and Cys106 [4][5]. Mild-to-moderate oxidative stress promotes an intramolecular disulfide bond between Cys23 and Cys45 while retaining Cys106 in a reduced thiol state [4]. This specific disulfide configuration exposes a hydrophobic nuclear export signal, engaging the exportin Chromosome Region Maintenance 1 (CRM1) pathway to shuttle HMGB1 through the nuclear pore complex into the cytoplasm [4][5]. Accumulation of cytosolic HMGB1 primes cells for sustained inflammatory and autophagic alterations preceding terminal fragmentation [4][5].

Extracellular HMGB1 Ligation via RAGE and TLR4 Drives Caspase Execution

Following cytoplasmic accumulation, sustained membrane destabilization and non-classical vesicular transport direct disulfide-HMGB1 into the extracellular space [4][5]. Extracellular HMGB1 operates as an endogenous damage-associated molecular pattern (DAMP), binding with high affinity to the receptor for advanced glycation end products (RAGE) and the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 2 (MD-2) signaling complex [5][6]. Ligation of the TLR4/MD-2 heterodimer by disulfide-HMGB1 triggers myeloid differentiation primary response 88 (MyD88) recruitment, initiating phosphorylation cascades that activate IκB kinase (IKK) and stimulate nuclear factor-κB (NF-κB p65) nuclear translocation [5][6]. In parallel, RAGE engagement induces receptor-mediated endocytosis and downstream phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), coordinating robust transcriptional upregulation of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 [5][6].

This HMGB1-directed inflammatory loop functions through autocrine and paracrine feedback to accelerate the intrinsic apoptotic execution machinery [5][6]. HMGB1-TLR4 signaling upregulates pro-apoptotic Bcl-2 family members while downregulating anti-apoptotic Bcl-2 and Bcl-xL [4][6]. Consequent oligomerization of Bax and Bak at the outer mitochondrial membrane facilitates mitochondrial outer membrane permeabilization (MOMP), promoting secondary release of cytochrome c and second mitochondria-derived activator of caspases (Smac/DIABLO) [2][5]. Cytosolic Smac/DIABLO binds and neutralizes X-linked inhibitor of apoptosis protein (XIAP), relieving inhibition on initiator Caspase-9 and executioner Caspase-3 [2][5]. Cleavage of pro-caspase-3 into active p17 and p12 subunits coordinates irreversible structural disassembly, evidenced by degradation of downstream cytoskeletal proteins and nuclear lamin processing, solidifying the transition toward apoptotic cell death [5][6].

Bifurcation Between Apoptotic Cleavage and Secondary Lytic Necrosis

Doxorubicin-treated cellular models diverge along distinct morphologic trajectories dictated by drug concentration and cell death duration [6][7]. At sub-micromolar concentrations, cells exhibit classical apoptotic landmarks characterized by cell shrinkage, chromatin condensation, membrane blebbing, and internucleosomal DNA fragmentation mediated by caspase-activated DNase [6]. However, when doxorubicin exposure reaches low micromolar thresholds—such as 6.88 μM observed in rat dorsal root ganglion neurons or standard anti-neoplastic regimens in H9c2 cardiomyoblasts—the cell death program shifts toward secondary necrotic lysis [6][7]. Active Caspase-3 specifically cleaves Gasdermin E (GSDME) at its conserved Asp270 residue, releasing the pore-forming N-terminal domain (GSDME-NT) [6]. GSDME-NT oligomerizes within the plasma membrane to generate large transmembrane pores of 10–14 nm internal diameter, driving cell swelling, dissipation of ionic gradients, and terminal membrane rupture [6].

This lytic pore transition facilitates unrestrained efflux of cellular constituents, converting silent apoptotic death into an intensely immunogenic phenotype [6]. Concurrently, mitochondrial reactive oxygen species induce the assembly of the NLRP3 inflammasome via recruitment of the adaptor protein ASC and pro-caspase-1 [6]. Caspase-1 activation mediates proteolytic maturation and externalization of interleukin-1β (IL-1β) and interleukin-18 (IL-18) [6]. Alongside cytokine discharge, the lytic membrane allows bulk release of secondary DAMPs, including ATP, heat shock proteins, and high-mobility group proteins [6]. Surface translocation of calreticulin functions alongside extracellular HMGB1 as primary immunogenic cell death (ICD) markers in MCF-7 breast adenocarcinoma models, recruiting antigen-presenting dendritic cells [6][8]. While this inflammatory cascade enhances tumor clearance, uncontrolled GSDME- and HMGB1-driven lytic degeneration in vascular endothelium and striated myocytes remains the dominant pathological mechanism underlying off-target tissue damage [2][6].

Analytical Methodologies for Redox Flux and Phenotypic Cell Death Profiling

Rigorous investigation of doxorubicin-mediated cytotoxicity demands targeted analytical workflows capable of discriminating primary free radical generation from fluorescent artifacts and downstream execution events [1][7]. Doxorubicin possesses intrinsic autofluorescence spanning excitation wavelengths of 470–495 nm and emission wavelengths of 560–600 nm, directly overlapping with standard redox-sensitive fluorophores [1][7]. To measure mitochondrial O₂^{\bullet-} with precision, researchers utilize MitoSOX Red with excitation adjusted to 510 nm and narrow bandpass emission filtering at 580 nm, or employ multispectral unmixing to isolate specific mitochondrial superoxide oxidation from parental anthracycline fluorescence [1][7]. Intracellular global hydroperoxide generation is quantified using 2′,7′-dichlorodihydrofluorescein diacetate (H₂DCF-DA) at 10 μM, incubated in dark conditions to prevent photo-oxidation, followed by emission measurement at 525 nm [7].

Quantification of reactive nitrogen species relies on the Griess diazotization reaction, which measures stable nitrite (NO₂-) metabolites in conditioned media as an indirect read-out of ^{\bulletNO} and ONOO- breakdown [7]. To quantify downstream membrane damage, the thiobarbituric acid reactive substances (TBARS) protocol measures MDA equivalents by heating cell lysates with 0.67% thiobarbituric acid under acidic conditions (100 °C for 45 minutes) followed by 1-butanol extraction and spectrophotometric measurement at 532 nm or 540 nm [7]. Subcellular HMGB1 dynamics are resolved via non-ionic detergent fractionation (0.1% NP-40) followed by immunoblotting with antibodies directed against acetylated Lys28/30 and total HMGB1, using lamin B1 and GAPDH as compartment controls [4][5]. Finally, temporal differentiation between early apoptosis and secondary lytic rupture is confirmed via kinetic flow cytometry using Annexin V-FITC/propidium iodide co-staining alongside fluorogenic Ac-DEVD-AMC cleavage assays, verifying the transition from intact membrane apoptosis to terminal permeability [6][7].

Table 1. Comparative Pharmacological, Binding Affinity, and Selectivity Benchmark of Doxorubicin (Adriamycin)

Parameter / CharacteristicDoxorubicin (Adriamycin)DaunorubicinMitoxantroneBiological Significance
Primary Target Affinity (Top2β Kd)2.4 μM3.1 μM0.85 μMDetermines DNA cleavage complex stabilization efficiency
Antiproliferative Potency (Mean IC50)0.12–0.45 μM0.18–0.60 μM0.05–0.22 μMBroad-spectrum tumor cytotoxicity across solid and hematologic lines
Quinone Redox Cycling Potential (V vs NHE)-0.328 V-0.335 V-0.450 VDictates rate of single-electron transfer to form semiquinone radical
Peroxynitrite Generation RateHigh (eNOS uncoupling)ModerateLow (minimal eNOS binding)Drives secondary nitrative DNA and cardiolipin oxidative decay
HMGB1 Nucleocytoplasmic MobilizationRobust (>8-fold export)Moderate (4–5-fold)Minimal (<2-fold)Triggers DAMP-mediated TLR4/RAGE inflammatory caspase amplification
Membrane Lysis MechanismCaspase-3 / GSDME cleavageCaspase-3 / GSDME cleavageCanonical apoptosisBifurcates apoptotic kinetics into secondary necrotic pore formation

Note: Comparison of anthracycline and anthracenedione chemotherapeutic parameters reflecting topoisomerase binding, redox cycling efficiency, and inflammatory DAMP mobilization.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

How do researchers circumvent doxorubicin autofluorescence artifacts when quantifying intracellular ROS?Experimental Model Selection

Doxorubicin exhibits broad intrinsic fluorescence with excitation maxima between 470 and 495 nm and emission spanning 560 to 600 nm [1][7]. When using hydroethidine or MitoSOX Red (which fluoresce in overlapping spectral ranges), investigators must employ rigorous fluorescence spectral unmixing algorithms or shift excitation to 510 nm while using narrow bandpass emission filters (580 ± 10 nm) [1][7]. Alternatively, researchers implement fluorescence-independent analytical methods such as electron paramagnetic resonance (EPR) spin trapping using DEPMPO or direct biochemical quantification of lipid peroxidation markers like malondialdehyde via HPLC-coupled TBARS assays [3][7].

What is the critical molecular determinant dictating whether HMGB1 functions as an apoptotic accelerator versus a cytokine?Target Biology & Mechanism

The functional activity of HMGB1 is dictated by the redox status of its three conserved cysteine residues: Cys23, Cys45, and Cys106 [4][5]. Under doxorubicin-induced moderate oxidative stress, an intramolecular disulfide bridge forms between Cys23 and Cys45, while Cys106 remains a free thiol; this disulfide-HMGB1 acts specifically as a high-affinity TLR4/MD-2 agonist that drives NF-κB activation and downstream apoptotic caspase signaling [4][5][6]. Fully reduced HMGB1 (all thiols intact) acts primarily as a chemokine via CXCR4, whereas terminally hyper-oxidized HMGB1 (all cysteines converted to sulfonic acid, \ce{C-SO3H}) loses both chemotactic and cytokine-inducing capacities [4][5].

Why does doxorubicin activate both apoptotic Caspase-3 and necrotic GSDME pore formation in the same model?Phenotypic Assays & Execution

The activation of both pathways represents an integrated continuum rather than mutually exclusive processes [6]. Doxorubicin-induced mitochondrial cardiolipin oxidation and MOMP activate canonical initiator Caspase-9 and executioner Caspase-3 [2][6]. When active Caspase-3 accumulates, it cleaves Gasdermin E (GSDME) at Asp270 if GSDME is expressed at sufficient levels in the target tissue [6]. Cleaved GSDME-NT translocates to the plasma membrane, forming lytic pores that accelerate secondary necrosis, transforming immunologically silent apoptotic cells into lytic corpses releasing ATP and HMGB1 [6][7].

References

  1. [1]. Smith MR, et al. Redox Biology. 2020;28:101311. [IF: 11.799]
  2. [2]. Gorini S, et al. Oxidative Medicine and Cellular Longevity. 2018;2018(1). [IF: 4.868]
  3. [3]. Yarana C, et al. Antioxidants. 2017;6(4):75.
  4. [4]. Shi S, et al. Cell Communication and Signaling. 2023;21(1).
  5. [5]. Syukri A, et al. Annals of Medicine &amp; Surgery. 2022;76.
  6. [6]. Vitale R, et al. International Journal of Molecular Sciences. 2024;25(13):7477. [IF: 4.9]
  7. [7]. Mahmoodazdeh A, et al. Iranian Journal of Basic Medical Sciences. 2020;23(9). [IF: 2.699]
  8. [8]. Alfaro Y, et al. Mol Cancer. 2013;12(1). [IF: 5.397]